ROHTO PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 2%, Exceeded Record Profit Forecast, Dividend Revised Upward by 1 Yen

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Nov 13, 2025 3:30 pm JST Earnings

4527 ROHTO PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

ROHTO PHARMACEUTICAL CO.,LTD. <4527> [TSE Prime] announced its financial results after the market closed on November 13th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2026 (April to September) expanded 24.6 billion yen, an increase 32.4% compared to the same period last year.

In addition, the full-year forecast for consolidated ordinary profit has been revised upward 2.3%, from the previous forecast of 43.0 billion yen to 44.0 billion yen (compared to 40.4 billion yen in the previous period), increasing the growth rate from 6.4% to 8.8%. The company has further increased its previous forecast of record profits for the first time in two years.

Based on the first-half performance announced by the company and the full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to decrease 11.2% from the same period last year to 19.3 billion yen.

In light of the strong performance, the company has increased its planned annual dividend for the current fiscal year from the original plan of 42 yen to 43 yen (compared to 36 yen in the previous period).

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit increased 34.3% from the same period last year, reaching 8.48 billion yen. The operating profit margin improved from 8.5% in the same period last year to 9.3%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	127,869	20,966	22,678	16,594	72.7	53.4	Nov 10, 2023	J-GAAP
Apr - Sep, 2024	139,082	17,791	18,590	12,921	56.6	46.0	Nov 13, 2024	J-GAAP
Apr - Sep, 2025	164,257	19,317	24,609	17,652	78.1	55.9	Nov 13, 2025	J-GAAP
YoY	+18.1%	+8.6%	+32.4%	+36.6%	+37.9%

First Half Results vs. Previous Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2025 Guidance	ー	ー	ー	ー	－	21	May 13, 2025	J-GAAP
Apr - Sep, 2025 Results	164,257	19,317	24,609	17,652	78.1	21	Nov 13, 2025	J-GAAP
Revision Rate	－	－	－	－	－

Guidance Update

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2026 Prev	334,500	39,000	43,000	31,500	139.4	42	Aug 6, 2025	J-GAAP
Mar, 2026 New	338,500	39,500	44,000	32,000	141.6	43	Nov 13, 2025	J-GAAP
Revision Rate	+1.2%	+1.3%	+2.3%	+1.6%	+1.6%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024	169,543	21,148	21,840	18,085	79.4	20	May 13, 2025	J-GAAP
Oct - Mar, 2025 Guidance	174,243	20,183	19,391	14,348	63.5	22	Nov 13, 2025	J-GAAP
YoY	+2.8%	-4.6%	-11.2%	-20.7%	-20.0%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	270,840	40,048	42,434	30,936	135.6	27	May 13, 2024	J-GAAP
Mar, 2025	308,625	38,939	40,430	31,006	136.1	36	May 13, 2025	J-GAAP
Mar, 2026 Guidance	338,500	39,500	44,000	32,000	141.6	43	Nov 13, 2025	J-GAAP
YoY	+9.7%	+1.4%	+8.8%	+3.2%	+4.0%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jul - Sep, 2024	70,726	6,001	6,317	4,439	19.5	8.5	Nov 13, 2024	J-GAAP
Oct - Dec, 2024	86,813	14,476	14,793	11,885	52.1	16.7	Feb 12, 2025	J-GAAP
Jan - Mar, 2025	82,730	6,672	7,047	6,200	27.2	8.1	May 13, 2025	J-GAAP
Apr - Jun, 2025	81,964	11,699	16,127	11,769	52.1	14.3	Aug 6, 2025	J-GAAP
Jul - Sep, 2025	82,293	7,618	8,482	5,883	26.0	9.3	Nov 13, 2025	J-GAAP
YoY	+16.4%	+26.9%	+34.3%	+32.5%	+33.8%